Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed, Refractory Multiple Myeloma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Very early researchNot Yet RecruitingNCT06298266
What this trial is testing

To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Guangdong Second Provincial General Hospital 15
Very early researchUnknownNCT04156269
What this trial is testing

BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
iCell Gene Therapeutics 12
Early research (Phase 1)UnknownNCT05438394
What this trial is testing

Clinical Study of Safety and Tolerability of Melphalan Hydrochloride for R/R MM

Who this might be right for
Multiple Myeloma
Peking University People's Hospital 24
Testing effectiveness (Phase 2)Study completedNCT00006379
What this trial is testing

Non-Ablative Allo HSCT For Hematologic Malignancies or SAA

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaLymphoma+5 more
Case Comprehensive Cancer Center 58
Testing effectiveness (Phase 2)Looking for participantsNCT05372354
What this trial is testing

Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Bristol-Myers Squibb 260
Testing effectiveness (Phase 2)Study completedNCT00482495
What this trial is testing

Bevacizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Mayo Clinic 42
Not applicableWithdrawnNCT00770419
What this trial is testing

Perceptions of Burden in Patients With Late-Stage Cancer and Their Caregivers

Who this might be right for
Brain and Central Nervous System TumorsChronic Myeloproliferative DisordersDepression+7 more
Rutgers, The State University of New Jersey
Testing effectiveness (Phase 2)Ended earlyNCT04119336
What this trial is testing

Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma

Who this might be right for
Relapsed Multiple MyelomaRefractory Multiple Myeloma
Andrew Yee, MD 2
Large-scale testing (Phase 3)Study completedNCT00478777
What this trial is testing

A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Celgene Corporation 150
Early research (Phase 1)Ended earlyNCT01309412
What this trial is testing

CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Pharmaceutical K.K. 9
Not applicableEnded earlyNCT00726830
What this trial is testing

Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer

Who this might be right for
Brain and Central Nervous System TumorsChronic Myeloproliferative DisordersLeukemia+8 more
M.D. Anderson Cancer Center 1
Not applicableUnknownNCT04447573
What this trial is testing

Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Hebei Senlang Biotechnology Inc., Ltd. 20
Early research (Phase 1)Active Not RecruitingNCT01562405
What this trial is testing

Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Massachusetts General Hospital 33
Very early researchLooking for participantsNCT07336823
What this trial is testing

JY232(JY232) Injection in Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Shenzhen Genocury Biotech Co., Ltd. 9
Testing effectiveness (Phase 2)Ended earlyNCT00006220
What this trial is testing

Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy

Who this might be right for
LeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm+1 more
Washington University School of Medicine 5
Testing effectiveness (Phase 2)Looking for participantsNCT07681596
What this trial is testing

A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
AstraZeneca 101
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07090954
What this trial is testing

GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma

Who this might be right for
Multiple Myeloma
Genrix (Shanghai) Biopharmaceutical Co., Ltd. 32
Early research (Phase 1)Study completedNCT03275103
What this trial is testing

Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

Who this might be right for
Multiple Myeloma
Genentech, Inc. 355
Early research (Phase 1)Study completedNCT01582295
What this trial is testing

XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease

Who this might be right for
Multiple Myeloma
Massachusetts General Hospital 4
Not applicableActive Not RecruitingNCT06062537
What this trial is testing

Analysis of Effectiveness and Safety of Teclistamab in Relapsed and Refractory Multiple Myeloma Patients

Who this might be right for
Multiple Myeloma
Intergroupe Francophone du Myelome 200
Next Page